Kesselheim AS - Search Results

1

Frequency Of Generic Drug Price Spikes And Impact On Medicaid Spending.

Patel AN, Kesselheim AS, Rome BN. Patel AN, et al. Among authors: kesselheim as. Health Aff (Millwood). 2021 May;40(5):779-785. doi: 10.1377/hlthaff.2020.02020. Health Aff (Millwood). 2021. PMID: 33939520

2

The rise and fall of Natrecor for congestive heart failure: implications for drug policy.

Kesselheim AS, Fischer MA, Avorn J. Kesselheim AS, et al. Health Aff (Millwood). 2006 Jul-Aug;25(4):1095-102. doi: 10.1377/hlthaff.25.4.1095. Health Aff (Millwood). 2006. PMID: 16835191

3

Extensions of intellectual property rights and delayed adoption of generic drugs: effects on medicaid spending.

Kesselheim AS, Fischer MA, Avorn J. Kesselheim AS, et al. Health Aff (Millwood). 2006 Nov-Dec;25(6):1637-47. doi: 10.1377/hlthaff.25.6.1637. Health Aff (Millwood). 2006. PMID: 17102189

4

Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.

Kesselheim AS, Mello MM. Kesselheim AS, et al. Health Aff (Millwood). 2007 Mar-Apr;26(2):483-91. doi: 10.1377/hlthaff.26.2.483. Health Aff (Millwood). 2007. PMID: 17339677 Review.

5

How Medicare could get better prices on prescription drugs.

Outterson K, Kesselheim AS. Outterson K, et al. Among authors: kesselheim as. Health Aff (Millwood). 2009 Sep-Oct;28(5):w832-41. doi: 10.1377/hlthaff.28.5.w832. Epub 2009 Jul 30. Health Aff (Millwood). 2009. PMID: 19643778

6

State generic substitution laws can lower drug outlays under Medicaid.

Shrank WH, Choudhry NK, Agnew-Blais J, Federman AD, Liberman JN, Liu J, Kesselheim AS, Brookhart MA, Fischer MA. Shrank WH, et al. Among authors: kesselheim as. Health Aff (Millwood). 2010 Jul;29(7):1383-90. doi: 10.1377/hlthaff.2009.0424. Health Aff (Millwood). 2010. PMID: 20606192 Free PMC article.

7

Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals.

Kesselheim AS, Outterson K. Kesselheim AS, et al. Health Aff (Millwood). 2010 Sep;29(9):1689-96. doi: 10.1377/hlthaff.2009.0439. Health Aff (Millwood). 2010. PMID: 20820028

8

False Claims Act prosecution did not deter off-label drug use in the case of neurontin.

Kesselheim AS, Darby D, Studdert DM, Glynn R, Levin R, Avorn J. Kesselheim AS, et al. Health Aff (Millwood). 2011 Dec;30(12):2318-27. doi: 10.1377/hlthaff.2011.0370. Health Aff (Millwood). 2011. PMID: 22147859

9

The Food and Drug Administration has the legal basis to restrict promotion of flawed comparative effectiveness research.

Kesselheim AS, Avorn J. Kesselheim AS, et al. Health Aff (Millwood). 2012 Oct;31(10):2200-5. doi: 10.1377/hlthaff.2012.0787. Health Aff (Millwood). 2012. PMID: 23048097

10

FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012.

Rome BN, Kramer DB, Kesselheim AS. Rome BN, et al. Among authors: kesselheim as. JAMA. 2014 Jan 22-29;311(4):385-91. doi: 10.1001/jama.2013.284986. JAMA. 2014. PMID: 24449317 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results